Influenza Virus Type A and B, SARS-CoV-2 (COVID-19) Antigen
Influenza A and B, RSV and Coronavirus SARS-CoV-2 Respiratory Panel is a multiplexed nucleic acid assay that simultaneous detects and identifies multiple respiratory viral pathogens including Coronavirus SARS-CoV-2, Influenza A and B and human Respiratory Syncytial virus.
Influenza A and B Virus
Influenza A and B are RNA viruses belonging to Orthomyxoviridae family. Both influenza A and B can cause disease with Influenza A infection been more severe. Influenza A can be subtyped by the hemagglutinin (H) and neuraminidase (N) genes; subtypes H1N1 and H3N2 are the strains that most commonly infect humans. Influenza is a highly contagious, acute, viral infection of the respiratory tract. It is a communicable disease that is easily transmitted through the coughing and sneezing of aerosolized droplets containing live virus. Influenza outbreaks occur each year during the fall and winter months. Rapid diagnostics with increased sensitivity are essential for the reliable detection of influenza A and B, allowing immediate, effective treatment decisions.
SARS-CoV-2 (COVID-19) Coronavirus
SARS-CoV-2 is a positive-sense, single-stranded RNA coronavirus (+ssRNA) belongs to the 2B group of the betacoronavirus family, which is the same family as SARS-CoV and MERS-CoV and has 70% similarity in genetic sequence to SARS. SARS-CoV-2 is the causative agent of coronavirus disease 2019 (COVID-19). Symptoms of COVID-19 range from mild fever, cough, and shortness of breath, muscle pain, diarrhea, and sore throat to pneumonia and multi-organ failure. The disease is transmitted from human-to-human by close contact, via respiratory droplets generated by sneezing and coughing. It may also spread when one touches a contaminated surface and then their face. The incubation period appears to be 2-14 days. Detection of the viral RNA by molecular method such as reverse transcriptase polymerase chain reaction (RT-PCR) is preferable and widely adopted test in COVID-19 testing, especially for early detection and infection spreading management.
- Diagnosis of COVID-19 Coronavirus infection
- Diagnosis of influenza virus infection
- Differential diagnosis of COVID-19 Coronavirus infection and Influenza infection
- Disease treatment and management
Positive results indicate infection with influenza virus or SARS-CoV-2.
Patient infection could be treated with antiviral therapy, especially young children; elderly and immunocompromised patients.
Negative (Non-reactive)
Immunochromatographic assay that utilizes lateral flow technology designed to detect and differentiate SARS-CoV-2 nucleocapsid antigen and Influenza A and B nucleoprotein antigens using enzyme immunoassay for detection. Other technology used, enzyme-linked immunosorbent assay (ELISA), RIDt- Immunofluorescence.
Nasopharyngeal swab, nasal swab, oropharyngeal swab collected in a viral transport media.
Stability
- Ambient: 1-3 days
- Refrigerated: 5-7 days
- Frozen: 30 days
- Curr Opin Pediatr. 2011 Feb;23(1):91-7. [PMID: 21150446]
- J Clin Virol. 2017 Aug 8;95:5-9. [PMID: 28818691]
- Future Microbiol. 2013 Apr;8(4):435-44. [PMID: 23534357]
- J Clin Virol. 2017 Jul 26;94:86-90. [PMID: 28772170]
- Alan H.B Wu. Tietz clinical guide to laboratory tests. 2006, Fourth edition. WB Saunders Company.
- David S Jacobs et al. Laboratory test Handbook. 2001, 5th edition. Lexi-Comp Inc
- Rapid Influenza Diagnostic Test. Atlanta, Georgia: Center for Disease Control;[ 8/8/2017],https://www.cdc.gov/flu/professionals/diagnosis/clinician_guidance_ridt.htm
- WHO information for molecular diagnosis of influenza virus – update, 3/2014: Geneva Swittzerland; World Health Organization